ExodusPoint Capital Management LP Has $14.75 Million Stake in 2seventy bio, Inc. (NASDAQ:TSVT)

ExodusPoint Capital Management LP boosted its position in 2seventy bio, Inc. (NASDAQ:TSVT) by 41.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,457,390 shares of the company’s stock after buying an additional 428,350 shares during the period. ExodusPoint Capital Management LP owned approximately 2.90% of 2seventy bio worth $14,749,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of TSVT. State Street Corp acquired a new position in 2seventy bio in the first quarter valued at $53,909,000. Wellington Management Group LLP acquired a new position in shares of 2seventy bio during the first quarter valued at about $42,854,000. BlackRock Inc. acquired a new position in shares of 2seventy bio during the first quarter valued at about $27,189,000. Balyasny Asset Management L.P. acquired a new position in shares of 2seventy bio during the first quarter valued at about $14,660,000. Finally, Vanguard Group Inc. acquired a new position in shares of 2seventy bio during the first quarter valued at about $23,549,000. Institutional investors and hedge funds own 98.49% of the company’s stock.

2seventy bio Price Performance

TSVT opened at $1.76 on Tuesday. 2seventy bio, Inc. has a fifty-two week low of $1.65 and a fifty-two week high of $16.17. The firm has a market capitalization of $89.10 million, a PE ratio of -0.45 and a beta of 1.49. The company’s 50-day moving average is $3.30 and its 200 day moving average is $7.07.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Guggenheim lowered shares of 2seventy bio from a “buy” rating to a “neutral” rating in a report on Tuesday, September 12th. Wedbush reiterated a “neutral” rating on shares of 2seventy bio in a report on Monday. Leerink Partnrs lowered shares of 2seventy bio from an “outperform” rating to a “market perform” rating in a report on Monday, October 30th. Morgan Stanley lowered shares of 2seventy bio from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $25.00 to $13.00 in a report on Friday, July 28th. Finally, Citigroup began coverage on shares of 2seventy bio in a report on Thursday, October 12th. They set a “buy” rating and a $13.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, 2seventy bio currently has a consensus rating of “Hold” and an average target price of $11.17.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma.